The cloning of the human renin receptor revealed that renin binding increases the catalytic efficiency of angiotensinogen conversion to angiotensin I fourfold and activates MAP kinases ERK1 and ERK2.
The identification of the first renin/prorenin receptor demonstrates that renin has direct cellular effects independent of angiotensin II and that membrane binding significantly increases its catalytic efficiency.
Renin is an aspartyl protease essential for the control of blood pressure and was long suspected to have cellular receptors. We report the expression cloning of the human renin receptor complementary DNA encoding a 350–amino acid protein with a single transmembrane domain and no homology with any known membrane protein. Transfected cells stably expressing the receptor showed renin- and prorenin-specific binding. The binding of renin induced a fourfold increase of the catalytic efficiency of angiotensinogen conversion to angiotensin I and induced an intracellular signal with phosphorylation of serine and tyrosine residues associated to an activation of MAP kinases ERK1 and ERK2. High levels of the receptor mRNA are detected in the heart, brain, placenta, and lower levels in the kidney and liver. By confocal microscopy the receptor is localized in the mesangium of glomeruli and in the subendothelium of coronary and kidney artery, associated to smooth muscle cells and colocalized with renin. The renin receptor is the first described for an aspartyl protease. This discovery emphasizes the role of the cell surface in angiotensin II generation and opens new perspectives on the tissue renin-angiotensin system and on renin effects independent of angiotensin II.
Nguyen et al. (Sat,) reported a other. Renin receptor cloning and characterization was evaluated on Renin receptor identification and functional characterization. The cloning of the human renin receptor revealed that renin binding increases the catalytic efficiency of angiotensinogen conversion to angiotensin I fourfold and activates MAP kinases ERK1 and ERK2.